Alnylam Pharma's market cap is currently $32.36B. The company's EPS TTM is $-2.172; its P/E ratio is ―; Alnylam Pharma is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is $-0.94. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Income Statement
Total Revenue	$ 2.25B	$ 1.83B	$ 1.04B	$ 844.29M	$ 492.85M
Gross Profit	$ 1.92B	$ 1.52B	$ 868.60M	$ 704.14M	$ 414.80M
Operating Income	$ -176.88M	$ -282.18M	$ -785.07M	$ -708.65M	$ -828.44M
EBITDA	$ -178.85M	$ -258.24M	$ -926.56M	$ -661.56M	$ -736.33M
Net Income	$ -278.16M	$ -440.24M	$ -1.13B	$ -852.82M	$ -858.28M
Balance Sheet
Cash & Short-Term Investments	$ 2.69B	$ 2.44B	$ 2.19B	$ 2.44B	$ 1.87B
Total Assets	$ 4.24B	$ 3.83B	$ 3.55B	$ 3.64B	$ 3.41B
Total Debt	$ 1.30B	$ 2.68B	$ 1.32B	$ 997.59M	$ 521.19M
Net Debt	$ -127.13M	$ 1.87B	$ 453.85M	$ 177.62M	$ 24.61M
Total Liabilities	$ 4.17B	$ 4.05B	$ 3.70B	$ 3.06B	$ 2.39B
Stockholders' Equity	$ 67.09M	$ -220.64M	$ -158.22M	$ 588.20M	$ 1.02B
Cash Flow
Free Cash Flow	$ -42.59M	$ 41.95M	$ -613.33M	$ -718.07M	$ -685.32M
Operating Cash Flow	$ -8.31M	$ 104.16M	$ -541.27M	$ -641.69M	$ -614.96M
Investing Cash Flow	$ -116.84M	$ -336.35M	$ 169.35M	$ -273.30M	$ -435.52M
Financing Cash Flow	$ 294.16M	$ 172.13M	$ 425.75M	$ 1.25B	$ 994.98M

Currency in USD

Alnylam Pharma Earnings and Revenue History

Income Statement >

Alnylam Pharma Debt to Assets

Balance Sheet >

Alnylam Pharma Cash Flow

Cash Flow >

Alnylam Pharma Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing